165 related articles for article (PubMed ID: 16134935)
1. Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
Lill MA; Winiger F; Vedani A; Ernst B
J Med Chem; 2005 Sep; 48(18):5666-74. PubMed ID: 16134935
[TBL] [Abstract][Full Text] [Related]
2. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
3. Comparative molecular field analysis (CoMFA) model using a large diverse set of natural, synthetic and environmental chemicals for binding to the androgen receptor.
Hong H; Fang H; Xie Q; Perkins R; Sheehan DM; Tong W
SAR QSAR Environ Res; 2003; 14(5-6):373-88. PubMed ID: 14758981
[TBL] [Abstract][Full Text] [Related]
4. Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.
Vedani A; Dobler M; Dollinger H; Hasselbach KM; Birke F; Lill MA
J Med Chem; 2005 Mar; 48(5):1515-27. PubMed ID: 15743194
[TBL] [Abstract][Full Text] [Related]
5. In silico prediction of receptor-mediated environmental toxic phenomena-application to endocrine disruption.
Lill MA; Dobler M; Vedani A
SAR QSAR Environ Res; 2005; 16(1-2):149-69. PubMed ID: 15844448
[TBL] [Abstract][Full Text] [Related]
6. Combining 4D pharmacophore generation and multidimensional QSAR: modeling ligand binding to the bradykinin B2 receptor.
Lill MA; Vedani A
J Chem Inf Model; 2006; 46(5):2135-45. PubMed ID: 16995744
[TBL] [Abstract][Full Text] [Related]
7. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.
Fang H; Tong W; Branham WS; Moland CL; Dial SL; Hong H; Xie Q; Perkins R; Owens W; Sheehan DM
Chem Res Toxicol; 2003 Oct; 16(10):1338-58. PubMed ID: 14565775
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.
Söderholm AA; Lehtovuori PT; Nyrönen TH
J Med Chem; 2005 Feb; 48(4):917-25. PubMed ID: 15715462
[TBL] [Abstract][Full Text] [Related]
9. Mixed-model QSAR at the glucocorticoid receptor: predicting the binding mode and affinity of psychotropic drugs.
Spreafico M; Ernst B; Lill MA; Smiesko M; Vedani A
ChemMedChem; 2009 Jan; 4(1):100-9. PubMed ID: 19009570
[TBL] [Abstract][Full Text] [Related]
10. Raptor: combining dual-shell representation, induced-fit simulation, and hydrophobicity scoring in receptor modeling: application toward the simulation of structurally diverse ligand sets.
Lill MA; Vedani A; Dobler M
J Med Chem; 2004 Dec; 47(25):6174-86. PubMed ID: 15566288
[TBL] [Abstract][Full Text] [Related]
11. Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor.
Vedani A; Dobler M; Lill MA
J Med Chem; 2005 Jun; 48(11):3700-3. PubMed ID: 15916421
[TBL] [Abstract][Full Text] [Related]
12. Simulating alpha/beta selectivity at the human thyroid hormone receptor: consensus scoring using multidimensional QSAR.
Vedani A; Zumstein M; Lill MA; Ernst B
ChemMedChem; 2007 Jan; 2(1):78-87. PubMed ID: 17096449
[TBL] [Abstract][Full Text] [Related]
13. Mixed-model QSAR at the human mineralocorticoid receptor: predicting binding mode and affinity of anabolic steroids.
Peristera O; Spreafico M; Smiesko M; Ernst B; Vedani A
Toxicol Lett; 2009 Sep; 189(3):219-24. PubMed ID: 19523507
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for androgen receptor agonists and antagonists: interaction of SPEED 98-listed chemicals and related compounds with the androgen receptor based on an in vitro reporter gene assay and 3D-QSAR.
Tamura H; Ishimoto Y; Fujikawa T; Aoyama H; Yoshikawa H; Akamatsu M
Bioorg Med Chem; 2006 Nov; 14(21):7160-74. PubMed ID: 16876421
[TBL] [Abstract][Full Text] [Related]
15. In silico prediction of harmful effects triggered by drugs and chemicals.
Vedani A; Dobler M; Lill MA
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):398-407. PubMed ID: 16045954
[TBL] [Abstract][Full Text] [Related]
16. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
17. SAR and QSAR modeling of endocrine disruptors.
Devillers J; Marchand-Geneste N; Carpy A; Porcher JM
SAR QSAR Environ Res; 2006 Aug; 17(4):393-412. PubMed ID: 16920661
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase.
Pan D; Tseng Y; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(5):1591-607. PubMed ID: 14502494
[TBL] [Abstract][Full Text] [Related]
19. Receptor flexibility in de novo ligand design and docking.
Alberts IL; Todorov NP; Dean PM
J Med Chem; 2005 Oct; 48(21):6585-96. PubMed ID: 16220975
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship study of a diverse set of estrogen receptor ligands (I) using MultiCASE expert system.
Klopman G; Chakravarti SK
Chemosphere; 2003 May; 51(6):445-59. PubMed ID: 12615096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
